Citation Impact
Citing Papers
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
2012 Science
Visualizing enveloping layer glycans during zebrafish early embryogenesis
2010 StandoutNobel
Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
2011
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
2013 StandoutScience
Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
2011
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
2013
A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
2012
eIF4E/4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies
2012
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
2010
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer
2013
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
2014
A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
2013
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
2017 Standout
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
2010
Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation
2015 StandoutNobel
Computationally designed sensors detect endogenous Ras activity and signaling effectors at subcellular resolution
2024 StandoutNobel
B-Raf and the inhibitors: from bench to bedside
2013
Cell mechanics and the cytoskeleton
2010 StandoutNature
Therapy-induced tumour secretomes promote resistance and tumour progression
2015 Nature
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
mTOR Signaling in Growth Control and Disease
2012 Standout
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
MEK in cancer and cancer therapy
2013
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
2011
A view on drug resistance in cancer
2019 StandoutNature
Tumor adaptation and resistance to RAF inhibitors
2013
Pathological roles of MAPK signaling pathways in human diseases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
2013
Therapeutic Strategies for Targeting Ras Proteins
2011
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Loss of centrosome integrity induces p38—p53—p21-dependent G1—S arrest
2006
LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells
2013
The multilayered complexity of ceRNA crosstalk and competition
2014 StandoutNature
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
A protein-interaction network of interferon-stimulated genes extends the innate immune system landscape
2019 StandoutNobel
A dimerization-dependent mechanism drives RAF catalytic activation
2009 Nature
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Targeting Mutant BRAF in Melanoma
2012
Tumor metastasis: moving new biological insights into the clinic
2013
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
2014
Lung cancer: current therapies and new targeted treatments
2016 Standout
Pancreatic Adenocarcinoma
2014 Standout
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
2015
mTOR Signaling in Growth, Metabolism, and Disease
2017 Standout
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
Aspirin Inhibits mTOR Signaling, Activates AMP-Activated Protein Kinase, and Induces Autophagy in Colorectal Cancer Cells
2012
Centriolin Anchoring of Exocyst and SNARE Complexes at the Midbody Is Required for Secretory-Vesicle-Mediated Abscission
2005
mTOR: from growth signal integration to cancer, diabetes and ageing
2010 Standout
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
2012
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
2011
Emerging Biological Principles of Metastasis
2017 Standout
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Making sense of cancer genomic data
2011
Programmed Cell Senescence during Mammalian Embryonic Development
2013 Standout
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
2013
Centriole Age Underlies Asynchronous Primary Cilium Growth in Mammalian Cells
2009
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Rapid, microwave-assisted organic synthesis of selective V600EBRAF inhibitors for preclinical cancer research
2012
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
2017
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
A Core Complex of BBS Proteins Cooperates with the GTPase Rab8 to Promote Ciliary Membrane Biogenesis
2007 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Ferroptosis: mechanisms, biology and role in disease
2021 Standout
The functions and regulation of the PTEN tumour suppressor
2012 Standout
The Hallmarks of Aging
2013 Standout
The PI3K Pathway in Human Disease
2017 Standout
Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
2015
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
2020 Nature
Metastatic colonization by circulating tumour cells
2016 StandoutNature
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
2015
AKAP signalling complexes: focal points in space and time
2004
Insulin disrupts β-adrenergic signalling to protein kinase A in adipocytes
2005 StandoutNatureNobel
Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress
2018
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
2014
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
2015
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
2016
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
2015 Standout
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
Cep97 and CP110 Suppress a Cilia Assembly Program
2007
Systems analysis of PKA-mediated phosphorylation gradients in live cardiac myocytes
2006 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
2012
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
2011
Metabolic reprogramming and cancer progression
2020 StandoutScience
Accurate proteome-wide missense variant effect prediction with AlphaMissense
2023 StandoutScienceNobel
A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective
2021
Works of Ensar Halilovic being referenced
PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
2010
Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer
2008
Therapeutic strategies for inhibiting oncogenic BRAF signaling
2008
4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
2010
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
2012
Centrosomal Anchoring of Protein Kinase C βII by Pericentrin Controls Microtubule Organization, Spindle Function, and Cytokinesis
2004
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
2010
A novel human protein of the maternal centriole is required for the final stages of cytokinesis and entry into S phase
2003